Handelsbanken Fonder’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $449K | Buy |
88,700
+15,100
| +21% | +$76.4K | ﹤0.01% | 1292 |
|
|
2025
Q1 | $389K | Hold |
73,600
| – | – | ﹤0.01% | 1326 |
|
|
2024
Q4 | $498K | Buy |
73,600
+4,100
| +6% | +$27.7K | ﹤0.01% | 1297 |
|
|
2024
Q3 | $458K | Buy |
69,500
+17,400
| +33% | +$115K | ﹤0.01% | 1282 |
|
|
2024
Q2 | $391K | Buy |
52,100
+18,000
| +53% | +$135K | ﹤0.01% | 1272 |
|
|
2024
Q1 | $340K | Hold |
34,100
| – | – | ﹤0.01% | 1338 |
|
|
2023
Q4 | $336K | Buy |
34,100
+11,700
| +52% | +$115K | ﹤0.01% | 1338 |
|
|
2023
Q3 | $171K | Hold |
22,400
| – | – | ﹤0.01% | 1500 |
|
|
2023
Q2 | $167K | Buy |
22,400
+3,600
| +19% | +$26.8K | ﹤0.01% | 1525 |
|
|
2023
Q1 | $125K | Hold |
18,800
| – | – | ﹤0.01% | 1512 |
|
|
2022
Q4 | $145K | Buy |
18,800
+5,500
| +41% | +$42.4K | ﹤0.01% | 1479 |
|
|
2022
Q3 | $142K | Hold |
13,300
| – | – | ﹤0.01% | 1488 |
|
|
2022
Q2 | $108K | Hold |
13,300
| – | – | ﹤0.01% | 1573 |
|
|
2022
Q1 | $95K | Hold |
13,300
| – | – | ﹤0.01% | 1686 |
|
|
2021
Q4 | $228K | Buy |
+13,300
| New | +$228K | ﹤0.01% | 1678 |
|